{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:09:31Z","timestamp":1791565771382,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,10,11]],"date-time":"2004-10-11T00:00:00Z","timestamp":1097452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2004,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the efficacy of glucosamine sulfate in knee osteoarthritis (OA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A 4\u2010center, 6\u2010month, randomized, double\u2010blind, placebo\u2010controlled glucosamine discontinuation trial was conducted in 137 current users of glucosamine with knee OA who had experienced at least moderate improvement in knee pain after starting glucosamine. Study medication dosage was equivalent to the dosage of glucosamine taken prior to the study (maximum 1,500 mg\/day). Followup continued for 6 months or until disease flare, whichever occurred first. The primary outcome was the proportion of disease flares in the glucosamine and placebo groups using an intent\u2010to\u2010treat analysis. Secondary outcomes included time to disease flare; analgesic medication use; severity of disease flare; and change in pain, stiffness, function and quality of life in the glucosamine and placebo groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Disease flare was seen in 28 (42%) of 66 placebo patients and 32 (45%) of 71 glucosamine patients (difference \u22123%; 95% confidence interval [95% CI] \u221219, 14; <jats:italic>P<\/jats:italic> = 0.76). In the Cox regression analysis, after adjustment for sex, study site, and OA radiographic severity, time to disease flare was not significantly different in the glucosamine compared with placebo group (hazard ratio of flare = 0.8; 95% CI 0.5, 1.4; <jats:italic>P<\/jats:italic> = 0.45). At final study visit, acetaminophen was used in 27% and 21% of placebo and glucosamine patients, respectively (<jats:italic>P<\/jats:italic> = 0.40), nonsteroidal antiinflammatory drugs were used in 29% and 30% (<jats:italic>P<\/jats:italic> = 0.92), and both were used in 20% and 21% (<jats:italic>P<\/jats:italic> = 0.84). No differences were found in severity of disease flare or other secondary outcomes between placebo and glucosamine patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with knee OA with at least moderate subjective improvement with prior glucosamine use, this study provides no evidence of symptomatic benefit from continued use of glucosamine sulfate.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.20697","type":"journal-article","created":{"date-parts":[[2004,10,11]],"date-time":"2004-10-11T19:35:08Z","timestamp":1097523308000},"page":"738-745","source":"Crossref","is-referenced-by-count":103,"title":["Randomized, double\u2010blind, placebo\u2010controlled glucosamine discontinuation trial in knee osteoarthritis"],"prefix":"10.1002","volume":"51","author":[{"given":"Jolanda","family":"Cibere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek A.","family":"Kopec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anona","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Canvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Esdaile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199808)41:8<1343::AID-ART3>3.0.CO;2-9"},{"key":"e_1_2_6_3_2","first-page":"591","article-title":"Knee osteoarthritis and physical functioning: evidence from the NHANES I epidemiologic followup study","volume":"18","author":"Davis MA","year":"1991","journal-title":"J Rheumatol"},{"issue":"43","key":"e_1_2_6_4_2","first-page":"19","article-title":"The effect of osteoarthritis on disability and health care use in Canada","volume":"22","author":"Badley EM","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780341104"},{"issue":"43","key":"e_1_2_6_6_2","first-page":"23","article-title":"Costs of osteoarthritis: estimates from a geographically defined population","volume":"22","author":"Gabriel SE","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_7_2","first-page":"43","article-title":"Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls","volume":"24","author":"Gabriel SE","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_6_8_2","first-page":"817","article-title":"Economics of osteoarthritis: a global perspective","volume":"11","author":"March LM","year":"1997","journal-title":"Clin Rheumatol"},{"key":"e_1_2_6_9_2","first-page":"1934","article-title":"An international comparison of the estimated effect of the aging of the population on the major cause of disablement, musculoskeletal disorders","volume":"22","author":"Badley EM","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007998009112035"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007998009112036"},{"key":"e_1_2_6_12_2","first-page":"260","article-title":"Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo\u2010controlled double\u2010blind investigation","volume":"3","author":"Drovanti A","year":"1980","journal-title":"Clin Ther"},{"key":"e_1_2_6_13_2","first-page":"504","article-title":"Glucosamine sulphate: a controlled clinical investigation in arthrosis","volume":"2","author":"D'Ambrosio E","year":"1981","journal-title":"Pharmatherapeutica"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007998209112375"},{"key":"e_1_2_6_15_2","first-page":"75","article-title":"Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee: a randomised, placebo\u2010controlled, double\u2010blind study","volume":"44","author":"Reichelt A","year":"1994","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1063-4584(05)80006-8"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1063-4584(05)80007-X"},{"key":"e_1_2_6_18_2","first-page":"469","article-title":"Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis","volume":"48","author":"Qiu GX","year":"1998","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_19_2","first-page":"2423","article-title":"Effect of glucosamine hydrochloride (GHcl) in the treatment of pain of osteoarthritis of the knee","volume":"26","author":"Houpt JB","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/ewjm.172.2.91"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.3.279"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.11.1469"},{"key":"e_1_2_6_23_2","first-page":"1628","article-title":"Glucosamine use in osteoarthritis: what is the evidence for its efficacy","volume":"26","author":"Cibere J","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03610-2"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.18.2113"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(03)00064-4"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)90163-U"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290816"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.16.4.494"},{"key":"e_1_2_6_30_2","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important participant relevant outcomes to antirheumatic drug therapy in participants with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy N","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_6_32_2","first-page":"2635","article-title":"Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis","volume":"27","author":"Ehrich EW","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1053\/joca.2000.0361"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.20697","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.20697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T09:21:31Z","timestamp":1697448091000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.20697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,11]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,10,15]]}},"alternative-id":["10.1002\/art.20697"],"URL":"https:\/\/doi.org\/10.1002\/art.20697","archive":["Portico"],"relation":{},"ISSN":["0893-7524","1529-0123"],"issn-type":[{"value":"0893-7524","type":"print"},{"value":"1529-0123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,11]]}}}